-

04:09:04 PM

LIVE Real Time BRPA Stock Market News

BRPA - Big Rock partners Acquisition Corp

04/19/21 3:57 PM

Nasdaq : BRPA

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis. However, NeuroRx was obligated to disclose

RHEA-AI

neutral

04/07/21 6:35 PM

NASDAQ : BRPA

Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal

Big Rock Partners Acquisition Corp. (Nasdaq:BRPA) ("Big Rock") today clarified the procedure for stockholder redemptions in connection with Big Rock's special meeting of stockholders called for the purpose of approving an amendment to Big Rock's amended

RHEA-AI

neutral

03/29/21 1:05 AM

Nasdaq, OTC : BRPA, RLFTF

NeuroRx Announces ZYESAMI(TM) (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

NeuroRx, Inc. today reports 60-day results of the Phase 2b /3 trial of intravenously-administered ZYESAMI(TM) (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration

RHEA-AI

neutral

03/26/21 9:35 AM

Nasdaq : BRPA

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI(TM) for the Treatment of COVID-19 Respiratory Failure

NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b /3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI(TM) (aviptadil acetate) for the treatment of critically-ill patients with COVID-19

RHEA-AI

neutral

03/15/21 7:15 AM

NASDAQ : BRPA

Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination

NeuroRx, Inc. ("NeuroRx"), a clinical stage-small molecule pharmaceutical company and Big Rock Partners Acquisition Corp. ("Big Rock") (NASDAQ:BRPA), a special purpose acquisition company, are pleased to announce that institutional

RHEA-AI

neutral

03/09/21 10:19 AM

Nasdaq : TFFP, BRPA

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement). Under the Feasibility Agreement, NeuroRx is delivering

RHEA-AI

neutral

02/23/21 1:11 PM

Nasdaq, OTC : BRPA, RLFTF

NeuroRx Announces that ZYESAMI(TM) (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

NeuroRx, Inc. announced today that the Phase 2b /3 trial* of ZYESAMI(TM) (aviptadil, previously RLF-100(TM)) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified

RHEA-AI

neutral

02/23/21 1:11 PM

Nasdaq : BRPA

NeuroRx Announces that ZYESAMI(TM) (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

NeuroRx, Inc. announced today that the Phase 2b /3 trial* of ZYESAMI(TM) (aviptadil, previously RLF-100(TM)) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified

RHEA-AI

neutral

02/09/21 8:13 AM

Nasdaq : BRPA

NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19

NeuroRx, Inc. today reported preliminary results from their Phase 2b /3 trial of ZYESAMI(TM) (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG (SIX:RLF; OTCQB:RLFTF) in patients with respiratory failure due to

RHEA-AI

neutral

02/09/21 7:30 AM

Nasdaq, OTC : BRPA, RLFTF

NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19

NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF; OTCQB: RLFTF) today reported preliminary results from the Phase 2b /3 trial of ZYESAMI(TM) (aviptadil, previously RLF-100) in patients with respiratory failure due to Critical COVID-19. The

RHEA-AI

neutral